Congenital Abnormalities Clinical Trial
Official title:
Assessment of Birth Outcomes in Eswatini After Transition to Dolutegravir-based Treatment
NCT number | NCT05883761 |
Other study ID # | EG0259 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 7, 2021 |
Est. completion date | September 30, 2023 |
Verified date | May 2023 |
Source | Elizabeth Glaser Pediatric AIDS Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens. The main question the study aims to answer is, what is the proportion of neural tube defects among live and stillborn infants delivered by: - HIV-positive women on DTG at conception - HIV-negative women - HIV-positive women on non-DTG ARV at conception Participants will be interviewed for information on HIV testing and antiretroviral therapy history, other medical history of selected conditions (e.g., diabetes, malaria, TB) and potential birth defect exposures. Photographs will be taken of the infants. Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) will be collected from patient records.
Status | Completed |
Enrollment | 50075 |
Est. completion date | September 30, 2023 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility | Surveillance component includes all deliveries/admissions as defined in study population description. For a subset of the population recruited for additional data collection: Inclusion Criteria: - women whose live or stillborn infant has birth defect as identified by a midwife or other clinician at the study hospital - willing to provide informed consent Exclusion Criteria: - unable to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Swaziland | Good Shepherd Hospital | Lubombo | |
Swaziland | Mankayane Government Hospital | Manzini | |
Swaziland | Raleigh Fitkin Memorial Hospital | Manzini | |
Swaziland | Mbabane Government Hospital | Mbabane | |
Swaziland | Hlathikhulu Hospital | Shiselweni |
Lead Sponsor | Collaborator |
---|---|
Elizabeth Glaser Pediatric AIDS Foundation | George Washington University, Ministry of Health Eswatini |
Swaziland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on DTG at conception. | Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on DTG at conception | 24 months | |
Primary | Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-negative women | Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-negative women | 24 months | |
Primary | Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on non-DTG ARV at conception | Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on non-DTG ARV at conception | 24 months | |
Secondary | Prevalence of major external birth defects among all live and stillborn infants regardless of maternal HIV or ART status. | Number of live and stillborn infants with major external birth defects divided by the total number of live and stillborn infants among all women regardless of HIV or ART status | 24 months | |
Secondary | Proportion of other pregnancy outcomes | Number of live and stillborn infants with low birthweight and pre-term delivery divided by the total number of live infants among women (overall and by HIV/ART status); number of stillborn infants among all pregnancies, including miscarriages | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00766571 -
Clinical and Genetic Studies of VACTERL Association
|
||
Recruiting |
NCT05394363 -
Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
|
||
Not yet recruiting |
NCT05393167 -
Congenital Anomalies in Infants of Diabetic Mother
|
||
Not yet recruiting |
NCT05547308 -
Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency
|
N/A | |
Recruiting |
NCT05151042 -
Digital Occlusal Wafer Versus Waferless Distal Segment Repositioning for BSSO in Skeletal Mandibular Deformities
|
N/A | |
Recruiting |
NCT05738954 -
Pattern Recognition and Anomaly Detection in Fetal Morphology Using Deep Learning and Statistical Learning
|
||
Recruiting |
NCT02505464 -
Pregnancies Complicated by Fetal Anomalies
|
||
Recruiting |
NCT02595307 -
Improving Informed Consent for Cleft Palate Repair
|
N/A | |
Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
Completed |
NCT00062452 -
Esophageal Motility and Airway Defenses Among Infants
|
N/A | |
Recruiting |
NCT05763615 -
3D Modeling of the Cervico-facial Region and Cranial Nerve Tractography: IMAG 2 ORL Project
|
N/A | |
Terminated |
NCT02351726 -
Mitroflow DL Post Approval Study- North America
|
N/A | |
Recruiting |
NCT04591392 -
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
|
N/A | |
Not yet recruiting |
NCT05231447 -
Birth Defect Registry in South West Region of France
|
||
Completed |
NCT01653392 -
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
|
||
Completed |
NCT02429947 -
An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients
|
N/A | |
Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT00362180 -
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
|
Phase 2 | |
Active, not recruiting |
NCT02987387 -
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
|
||
Completed |
NCT02875860 -
'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial
|
Phase 2 |